Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company, ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Among a plethora of weight-management plans and dietary charts (namely, keto, dash, sirtfood, paleo or crash diet), climbing ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss. Shares rose 12% to $35.01 in pre-market trading ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

Around 1.5 million Brits are now taking weight-loss drugs, such as Mounjaro, and pharmacists are warning users to be careful in the heatwave ...